ENG/中
老虎證券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
諾誠健華
成交量:
- -
成交額:
- -
市值:
- -
市盈率:
- -
高:
- -
開:
- -
低:
- -
收:
- -
資料載入中...
總覽
公司
新聞
公告
諾誠健華:公司新藥奧布替尼獲批在國內開展臨牀II期研究
格隆汇
·
2021-04-15
港股異動 | 諾誠健華-B(09969)漲超7% 奧布替尼獲國家藥監局批准開展治療多發
金融界网站
·
2021-04-14
諾誠健華-B(09969-HK)漲8.85%
财华社
·
2021-04-14
諾誠健華奧布替尼獲國家藥監局批准開展治療多發性硬化臨牀II期研究
美通社
·
2021-04-14
諾誠健華-B(09969)委任謝榕剛為非執行董事
智通财经网
·
2021-03-31
高盛:予諾誠健華-B(09969)“買入”評級 目標價升至21港元
智通财经
·
2021-03-30
高盛上調諾誠健華-B(09969.HK)目標價至21元 評級「買入」
AAFN
·
2021-03-30
6至8個藥物將進入臨牀,諾誠健華研發支出接近翻番
腾讯自选股
·
2021-03-26
諾誠健華-B(09969.HK)年度虧損減少至4.64億元 研發成本達4.03億元
格隆汇
·
2021-03-26
諾誠健華-B(09969)2020年年內虧損約4.64億元 同比減少約78.41%
智通财经
·
2021-03-26
諾誠健華-B(09969.HK)全年虧損收窄至4.64億元人民幣
AAFN
·
2021-03-26
諾誠健華-B盤中異動 下午盤股價大跌5.13%
自选股智能写手
·
2021-03-19
諾誠健華-B(09969-HK)漲3.65%
财华社
·
2021-03-18
【異動股】諾誠健華-B(09969-HK)漲3.65%
金融界网站
·
2021-03-18
施一公創立的諾誠健華擬科創板上市,港股大漲至近300億港元
DeepTech深科技
·
2021-03-15
諾誠健華(09969),在香港IPO不到一年,就準備A股上市
腾讯自选股
·
2021-03-13
諾誠健華開升逾5% 擬發A股上海科創板上市
经济通中国站
·
2021-03-12
資本加持仍持續虧損!諾誠健華想回科創板上市 有施一公助陣也不好辦
时代财经
·
2021-03-12
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/90009/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"90009","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"90009\",,,,,undefined,":{"symbol":"90009","market":"HK","secType":"STK","nameCN":"諾誠健華","latestPrice":0,"timestamp":1748592000000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":25034000,"shares":225290000,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"05-30 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1748827800000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1748568600000,1748577600000],[1748581200000,1748592000000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"諾誠健華","latestPrice":24.02,"timestamp":1748588400000,"preClose":22.99,"halted":0,"volume":7613700,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"90009\",,,,,undefined,":{"symbol":"90009","floatShares":25034000,"roa":"--","roe":"--","lyrEps":0,"shares":225290000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"90009\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2127072585","title":"諾誠健華:公司新藥奧布替尼獲批在國內開展臨牀II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2127072585","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127072585?lang=zh_tw&edition=fundamental","pubTime":"2021-04-15 09:25","pubTimestamp":1618449900,"startTime":"0","endTime":"0","summary":"【诺诚健华:公司新药奥布替尼获批在国内开展临床II期研究】4月14日,诺诚健华宣布,公司旗下布鲁顿酪氨酸激酶(BTK)抑制剂奥布替尼用于治疗多发性硬化(MS)已经通过中国国家药品监督管理局(NMPA)...","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202104151885438464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","90009"],"gpt_icon":0},{"id":"2127252770","title":"港股異動 | 諾誠健華-B(09969)漲超7% 奧布替尼獲國家藥監局批准開展治療多發","url":"https://stock-news.laohu8.com/highlight/detail?id=2127252770","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127252770?lang=zh_tw&edition=fundamental","pubTime":"2021-04-14 15:41","pubTimestamp":1618386116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,诺诚健华-B宣布,公司旗下布鲁顿酪氨酸激酶抑制剂奥布替尼用于治疗多发性硬化已经通过中国国家药品监督管理局的临床研究用新药审评,获批在中国开展临床II期研究。截至发稿,诺诚健华涨7.03%,报20.55港元,成交额1.99亿港元。2020年11月,奥布替尼获美国FDA批准开展治疗多发性硬化临床II期研究。","market":"hk","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2021/04/14154132371805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["90009","09969"],"gpt_icon":0},{"id":"2127047291","title":"諾誠健華-B(09969-HK)漲8.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2127047291","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127047291?lang=zh_tw&edition=fundamental","pubTime":"2021-04-14 13:42","pubTimestamp":1618378920,"startTime":"0","endTime":"0","summary":"诺诚健华-B(09969-HK)截至13:41上涨8.85%,现报20.9港元,涨1.7港元。成交518万股,涉资1.054亿元。","market":"us","thumbnail":"https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202104141884108958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","90009"],"gpt_icon":0},{"id":"2127047898","title":"諾誠健華奧布替尼獲國家藥監局批准開展治療多發性硬化臨牀II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2127047898","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127047898?lang=zh_tw&edition=fundamental","pubTime":"2021-04-14 09:37","pubTimestamp":1618364220,"startTime":"0","endTime":"0","summary":"2020年11月,奥布替尼获美国FDA批准开展治疗多发性硬化临床II期研究。奥布替尼是诺诚健华自主研发的具高度靶标选择性的新型BTK抑制剂,可用于治疗自身免疫性疾病,目前正在中国及美国进行多中心、多适应症的临床试验,显示了良好的靶点占有率和安全性。现有多个新药产品处于商业化、临床及临床前研发阶段。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-04-14/doc-ikmyaawa9565055.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-04-14/doc-ikmyaawa9565055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90009","09969"],"gpt_icon":0},{"id":"2123224119","title":"諾誠健華-B(09969)委任謝榕剛為非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2123224119","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2123224119?lang=zh_tw&edition=fundamental","pubTime":"2021-03-31 19:52","pubTimestamp":1617191578,"startTime":"0","endTime":"0","summary":"诺诚健华-B(09969)公布,林利军辞任非执行董事,自2021年3月31日起生效...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_16.jpeg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_16.jpeg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/440608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["90009","09969"],"gpt_icon":0},{"id":"2123260880","title":"高盛:予諾誠健華-B(09969)“買入”評級 目標價升至21港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2123260880","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2123260880?lang=zh_tw&edition=fundamental","pubTime":"2021-03-30 14:52","pubTimestamp":1617087130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,高盛发布研究报告,予诺诚健华-B“买入”评级,目标价升至21港元。该行表示,公司在研的BTK抑制剂奥布替尼今年首季商业化进度理想,正计划将销售团队扩充至200人,今年内覆盖内地900家医院。另外,该行认为今年下半年潜在的国家医保药品目录谈判或为诺诚健华今年的增长动力之一,参考市场上其他BTK抑制剂Brukinsa及Imbruvica定价,认为对BTK抑制剂市场价格有支持作用。","market":"hk","thumbnail":"https://static.tigerbbs.com/8e87285f5f61644eaba65898e6ccf2bf","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8e87285f5f61644eaba65898e6ccf2bf"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/438372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["90009","09969"],"gpt_icon":0},{"id":"2123267208","title":"高盛上調諾誠健華-B(09969.HK)目標價至21元 評級「買入」","url":"https://stock-news.laohu8.com/highlight/detail?id=2123267208","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2123267208?lang=zh_tw&edition=fundamental","pubTime":"2021-03-30 14:01","pubTimestamp":1617084088,"startTime":"0","endTime":"0","summary":"高盛发表研究报告指,诺诚健华-B 去年下半年录亏损5,700万元人民币,主要来自研发费用按年增长45%及营销及一般行政费用增长104%,但亏损已较2019年同期的2.43亿元人民币大幅减少。高盛对诺诚健华予以「买入」评级,以反映2月份配股所得资金,以及公司将於今明两年加大研发投入,但预期今年及明年净亏损5.85亿及3.01亿元人民币,目标价上调至21元。","market":"us","thumbnail":"https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1087753&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["09969","90009"],"gpt_icon":0},{"id":"2122740361","title":"6至8個藥物將進入臨牀,諾誠健華研發支出接近翻番","url":"https://stock-news.laohu8.com/highlight/detail?id=2122740361","media":"腾讯自选股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2122740361?lang=zh_tw&edition=fundamental","pubTime":"2021-03-26 20:42","pubTimestamp":1616762520,"startTime":"0","endTime":"0","summary":"6至8个药物将进入临床,诺诚健华研发支出接近翻番 来源:北京日报客户端在接下来的18个月,诺诚健华将有6至8个候选药物进入临床,从而使其进入临床阶段的药物将增加到10多个。3月26日,北京生物医药高科技公司诺诚健华发布的2020年全年业绩报告和公司进展还显示,其研发支出已由2019年的2.131亿元增加到2020年的4.028亿元。其现有多个新药产品已处于商业化、临床及临床前研发阶段。","market":"us","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-26/doc-ikknscsk1885255.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-26/doc-ikknscsk1885255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90009"],"gpt_icon":0},{"id":"2122479820","title":"諾誠健華-B(09969.HK)年度虧損減少至4.64億元 研發成本達4.03億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2122479820","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2122479820?lang=zh_tw&edition=fundamental","pubTime":"2021-03-26 19:21","pubTimestamp":1616757668,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨诺诚健华-B发布公告,截至2020年12月31日止年度,公司收益由上年度的人民币120万元增加至人民币140万元,主要由于南京诺诚健华向第三方提供的服务订单增加所致。年内亏损由上年度的人民币21.5亿元减少至该年度的人民币4.64亿元。研发成本由上年度的人民币2.13亿元增加至该年度的人民币4.03亿元,该增加主要是由于公司扩展临床试验及股份支付增加所致。","market":"us","thumbnail":"https://static.tigerbbs.com/cb94707725a5c97e34b5305626765aec","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb94707725a5c97e34b5305626765aec"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/news/detail.html?id=503202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["09969","90009"],"gpt_icon":0},{"id":"2122479806","title":"諾誠健華-B(09969)2020年年內虧損約4.64億元 同比減少約78.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2122479806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2122479806?lang=zh_tw&edition=fundamental","pubTime":"2021-03-26 19:19","pubTimestamp":1616757543,"startTime":"0","endTime":"0","summary":"智通财经APP讯,诺诚健华-B 公布2020年业绩,收益约人民币136.4万元,同比增长9.4%;其他收入及收益增加159.9%至2.71亿元;研发成本约4.03亿元,同比增长89%;年内亏损约4.64亿元,同比减少约78.41%;每股亏损0.48元,不派息。研发成本增加主要归因于:研发僱员成本由人民币5020万元增加至8370万元;第三方合约成本由人民币3830万元增加至5530万元;直接临床试验开支由人民币3750万元增加至5070万元;及以股份支付薪酬由人民币5720万元增加至1.716亿元。","market":"hk","thumbnail":"https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/436102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","90009"],"gpt_icon":0},{"id":"2122092476","title":"諾誠健華-B(09969.HK)全年虧損收窄至4.64億元人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2122092476","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2122092476?lang=zh_tw&edition=fundamental","pubTime":"2021-03-26 19:09","pubTimestamp":1616756987,"startTime":"0","endTime":"0","summary":"诺诚健华-B 公布截至去年12月底止全年业绩,营业额136.4万元人民币(下同),按年升9.4%。亏损收窄至4.64亿元,上年同期蚀21.41亿元;每股亏损0.48元。不派息。(ek/k)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":"https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1086591&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["UCmain","CNHmain","CYB","09969","90009"],"gpt_icon":0},{"id":"2120112747","title":"諾誠健華-B盤中異動 下午盤股價大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2120112747","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2120112747?lang=zh_tw&edition=fundamental","pubTime":"2021-03-19 13:32","pubTimestamp":1616131939,"startTime":"0","endTime":"0","summary":"2021年03月19日下午盘13时32分,诺诚健华-B股票出现异动,股价大幅下跌5.13%。截至发稿,该股报18.900港元/股,成交量344.8万股,换手率0.23%,振幅4.52%。诺诚健华-B股票所在的生物技术行业中,整体跌幅为6.98%。诺诚健华-B公司简介:诺诚健华医药有限公司是一家主要从事生物医药业务的投资控股公司。消息层面,截至13时32分,诺诚健华-B股票正面舆情新闻比例25%。","market":"hk","thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202103191332197dce4447&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202103191332197dce4447&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","90009"],"gpt_icon":0},{"id":"2120925169","title":"諾誠健華-B(09969-HK)漲3.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2120925169","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2120925169?lang=zh_tw&edition=fundamental","pubTime":"2021-03-18 15:43","pubTimestamp":1616053380,"startTime":"0","endTime":"0","summary":"原标题:【异动股】诺诚健华-B(09969-HK)涨3.65%诺诚健华-B(09969-HK)截至15:39上涨3.65%,现报19.9港元,涨0.7港元。成交506万股,涉资1.007亿元。(文章来源:财华社)","market":"hk","thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202103181748247c07bfb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202103181748247c07bfb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","90009"],"gpt_icon":0},{"id":"2120648156","title":"【異動股】諾誠健華-B(09969-HK)漲3.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2120648156","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2120648156?lang=zh_tw&edition=fundamental","pubTime":"2021-03-18 15:39","pubTimestamp":1616053190,"startTime":"0","endTime":"0","summary":"【财华社讯】诺诚健华-B(09969-HK)截至15:39上涨3.65%,现报19.9港元,涨0.7港元。成交506万股,涉资1.007亿元。(出处:FinetAI)","market":"us","thumbnail":"https://static.tigerbbs.com/76824cd4c5b97eaacdaab63d96995a28","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/76824cd4c5b97eaacdaab63d96995a28"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2021/03/18153932157047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09969","90009"],"gpt_icon":0},{"id":"2119892970","title":"施一公創立的諾誠健華擬科創板上市,港股大漲至近300億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2119892970","media":"DeepTech深科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2119892970?lang=zh_tw&edition=fundamental","pubTime":"2021-03-15 16:28","pubTimestamp":1615796880,"startTime":"0","endTime":"0","summary":"施一公创立的诺诚健华拟科创板上市,港股大涨至近300亿港元 来源:DeepTech深科技2021年3月11日,诺诚健华董事会决议拟发行人民币股份及于上海证券交易所科创板上市。2021年3月12日,诺诚健华市值已接近300亿港元,达到了291亿港元。自成立以来,诺诚健华深受资本青睐,2020年3月,诺诚健华通过适用“港股18A”新政的方式登陆港交所,募资资金超20亿港元。","market":"sh","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-15/doc-ikknscsi5282060.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-15/doc-ikknscsi5282060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90009"],"gpt_icon":0},{"id":"2119998545","title":"諾誠健華(09969),在香港IPO不到一年,就準備A股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2119998545","media":"腾讯自选股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2119998545?lang=zh_tw&edition=fundamental","pubTime":"2021-03-13 11:18","pubTimestamp":1615605508,"startTime":"0","endTime":"0","summary":"诺诚健华,在香港IPO不到一年,就准备A股上市 来源:瑞恩资本RyanbenCapital3月11日,诺诚健华发布公告,董事会已决议发行人民币股份,并于上海证券交易所科创板上市。诺诚健华,于2020年3月23日在港交所挂牌上市,当时募资 25.76 亿港元。目前,诺诚健华拥有18 条针对癌症和自身免疫疾病的在研管线,适用于中国病人高发的淋巴瘤、肝癌、胆管癌、尿路上皮癌等多种恶性肿瘤及自身免疫类疾病。截至昨日,诺诚健华收报每股18.50港元,其总市值为277.44亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-13/doc-ikkntiam0170383.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-13/doc-ikkntiam0170383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90009"],"gpt_icon":0},{"id":"2118370349","title":"諾誠健華開升逾5% 擬發A股上海科創板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2118370349","media":"经济通中国站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2118370349?lang=zh_tw&edition=fundamental","pubTime":"2021-03-12 09:52","pubTimestamp":1615513920,"startTime":"0","endTime":"0","summary":"诺诚健华(09969)开升5.19%,报19.46元,逼近廿天平均线(19.729元),以现价计,该股暂连升3日,累计升幅16.67%。该股成交约3万股,涉资62万元。诺诚健华公布,董事会决议拟发行人...","market":"us","thumbnail":"https://static.tigerbbs.com/0dadac519bb6258dbafe32faf8a03d89","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0dadac519bb6258dbafe32faf8a03d89"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202103121841419444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["90009"],"gpt_icon":0},{"id":"2118793266","title":"資本加持仍持續虧損!諾誠健華想回科創板上市 有施一公助陣也不好辦","url":"https://stock-news.laohu8.com/highlight/detail?id=2118793266","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2118793266?lang=zh_tw&edition=fundamental","pubTime":"2021-03-12 08:55","pubTimestamp":1615510508,"startTime":"0","endTime":"0","summary":"当前,科创板整体估值尚在调整之中,如果诺诚健华此次科创板上市没能赶到整体走势上升的区间,可能将无法延续前次IPO的热度。在港交所“云敲锣”仅一年,创新药新贵诺诚健华(09969.HK)再推 ...","market":"sh","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20210312/c627715715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["90009"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/90009\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"90009\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"90009\",market:\"HK\",delay:false,,,undefined,":{}}}